Director at Design Therapeutics (DSGN) awarded options on 30,000 shares

Rhea-AI Filing Summary

Design Therapeutics, Inc. reported that director Justin D. Gover received a grant of stock options covering 30,000 shares of common stock. The options have an exercise price of $10.55 per share and expire on June 8, 2036. The award vests in equal monthly installments over 12 months following June 9, 2026, and will in any case be fully vested by the date of the company’s next annual meeting of stockholders. Following this grant, Gover holds 30,000 stock options directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Gover Justin D.

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	30,000	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 30,000 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Option grant size: 30,000 options Exercise price: $10.55 per share Expiration date: June 8, 2036 +3 more

6 metrics

Option grant size 30,000 options Stock Option (right to buy) granted to Justin D. Gover

Exercise price $10.55 per share Conversion or exercise price of stock options

Expiration date June 8, 2036 Option expiration for Gover’s grant

Underlying shares 30,000 shares Common Stock underlying the option grant

Total options after grant 30,000 options Total derivative securities following transaction

Vesting schedule 12 monthly installments Vests over 12 months after June 9, 2026

Key Terms

Stock Option (right to buy), exercise price, expiration date, vesting, +1 more

5 terms

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy)"

exercise price financial

"conversion_or_exercise_price: 10.5500"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: 2036-06-08T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

vesting financial

"shares subject to the option vest in equal monthly installments over 12 months"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Gover Justin D.

(Last) (First) (Middle)

C/O DESIGN THERAPEUTICS, INC.

6005 HIDDEN VALLEY ROAD, SUITE 110

(Street)

CARLSBAD CALIFORNIA 92011

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Design Therapeutics, Inc. [ DSGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$10.55	06/09/2026		A		30,000		(1)	06/08/2036	Common Stock	30,000	$0	30,000	D

Explanation of Responses:

1. The shares subject to the option vest in equal monthly installments over 12 months following June 9, 2026 provided that the shares subject to the option will in any case be fully vested on the date of the Company's next annual meeting of stockholders.

	/s/ Mustapha Parekh, Attorney-in-Fact	06/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Design Therapeutics (DSGN) disclose for Justin D. Gover?

Design Therapeutics disclosed that director Justin D. Gover received a grant of stock options for 30,000 shares of common stock. The options were awarded with a transaction code “A,” indicating a grant, award, or other acquisition rather than an open-market purchase or sale.

How many Design Therapeutics (DSGN) shares are covered by Justin Gover’s new stock options?

The stock option grant to Justin Gover covers 30,000 shares of Design Therapeutics common stock. These options give him the right to buy up to that number of shares, subject to vesting conditions and the specified exercise price and expiration date.

What is the exercise price and expiration date of Justin Gover’s DSGN stock options?

Justin Gover’s stock options have an exercise price of $10.55 per share and expire on June 8, 2036. This means he may purchase Design Therapeutics common shares at $10.55 any time after vesting and before the June 8, 2036 expiration date.

How do Justin Gover’s Design Therapeutics (DSGN) options vest over time?

The options granted to Justin Gover vest in equal monthly installments over 12 months following June 9, 2026. The footnote also states the options will in any case be fully vested by the date of Design Therapeutics’ next annual meeting of stockholders, whichever occurs first.

Is Justin Gover’s DSGN stock option grant an open-market transaction?

No, the filing classifies Justin Gover’s transaction with code “A,” indicating a grant, award, or other acquisition. This reflects a compensation-related stock option grant from Design Therapeutics rather than an open-market buy or sell of existing common shares.

How many stock options does Justin Gover hold in DSGN after this grant?

After the reported transaction, Justin Gover holds 30,000 stock options directly. The Form 4 shows this as the total number of derivative securities following the transaction, all relating to options on Design Therapeutics common stock from this single reported grant.